CEO MONTHLY / ISSUE 9 2023 9 Mar23134 What do you value in your team and how does Kent Athlone Pharma Group cultivate a rich environment for personal and professional growth? Over the last 12 months, one thing that has always impressed me, has been the level of commitment from our team, the desire to get it right for our customers every day, and the level of collaboration across every function across the business. We have a great team which I am very proud of. Within Kent Athlone Pharma Group, we call this the “One Team” culture, and it is something we have really focussed on and invested in bringing to life in everything that we do. We have taken the time to re-define our company values, and they guide our approach in everything that we do: Honesty, Teamwork, Diversity, Commitment, Agility, and Leadership. When we are recruiting in addition to the right experience, we also think very carefully about if the cultural fit is there for both parties. This is a fast-moving, action-orientated, hands-on culture where “smart, goalorientated, precise, driven, do’ers” thrive. It is not for the faint-hearted, but it is a stimulating environment for the right people, who enjoy learning/collaborating, where individuals are provided with genuine autonomy to drive the business forwards and take pride in making a difference every day. We proactively invest in frequent and engaging communication/events with the whole team, so everyone is kept informed, all of the time, and has the opportunity to share their views openly, make suggestions for improvement and ask questions freely. The biggest investment that we make every year as a business is in our people. To finish, what are your plans for the future? Our 5-year growth strategy is focussed on five pillars: • Expand the Product Portfolio: Through pro-active Business Development, Partnering and New Product Development. Our focus going forwards will be differentiated Value Added Medicines, in 5 core therapy areas: Anti-Infectives, Pain, Ophthalmology, Oncology, Hospital Injectables. • Effectively launch and commercialise: Working closely with our partners, and regulatory bodies to launch products on time, and then effectively promoting/ distributing these products to achieve commercial expectations. • Expand the presence Internationally: Of our product range either via direct distribution or partnering. • Improve Operational Excellence: Effectively managing our supply chain, and business functions via streamlined, integrated and automated applications, systems and processes. • Build and maintain a High Performance Culture: That attracts, retains, develops and engages a high calibre, diverse team. In summary the future outlook for Kent Athlone Pharma Group looks strong. We have a clear Growth Strategy, a Great Team a positive Company Culture, and the ambition to do everything we can to get it right for our customers, partners and the patients we serve, every day. We appreciate hearing from Terry as he secures the title of Most Influential Pharmaceutical Products Development & Supply CEO 2023 – UK from CEO Monthly. Contact: Terry Petersen Company: Kent Athlone Pharma Group Web Address: www.kentpharm.co.uk/ Customer Focus “ Kent Pharma’s ethos is customer excellence. We strive to fulfil all of our customer requirements efficiently and professionally. Everything we do is centred around our customers as they are key to our business growth and success - Nicola Roche, Wholesale Director. ” Strong Financial Planning and Control “ The business has a renewed focus on a strong controls’ environment; ensuring the completeness and accuracy of data to allow for timely decision making. Focussing on the key performance indicators across the business allows us to prioritise those things that are most impactful in strengthening our business and continuing to deliver growth - Adrian Narayan, Chief Financial Officer.” International expansion “ We are in a very exciting period for Kent Athlone Pharma Group as the business is implementing an international expansion strategy through direct distribution or partnerships. This will not only enable the business to¬ build a platform to layer on new growth opportunities in new territories, but it will also provide development opportunities for staff to gain international experience. “The business is building on its’ extensive experience of commercialising Value-Added Medicines by investing in a program of activities to optimise commercial capabilities. This will ensure Kent Athlone Pharma Group has the right commercial structure and capabilities, underpinned by robust processes to deliver the ambitious growth plans - Andy Crichton, International Business and Strategic Projects Director ”
RkJQdWJsaXNoZXIy MTUyMDQwMA==